Lipigon presents at the ELC scientific meeting in Tutzing, GermanyLipigon Pharmaceuticals AB ("Lipigon") is presenting at the European Lipoprotein Club's scientific meeting in Tutzing, Germany, on September 11-14. Fredrik Landfors, Clinical Scientist at Lipigon, will give a presentation at the European Lipoprotein Club (ELC) annual scientific meeting that starts today in Tutzing, Germany.
"ELC is one of the most pivotal gatherings for researchers in our field. I look forward to presenting Lipigon's genetic validation of ANGPTL4 as a drug target. It is of great importance to present data that strengthens and validates ANGPTL4. Our target is one of few new targets with strong scientific support for reducing the risk of cardiovascular diseases by lowering blood fats," says Fredrik Landfors.
ELC is the oldest and most active European network in the lipid field. It was established in 1977 and Thomas Olivecrona was a member of the first organizing committee. The primary goal of ELC is to facilitate collaboration and the exchange of ideas in basic and clinical research concerning lipoproteins (complexes of blood lipids). Today, the network comprises over 500 researchers from more than 20 countries across Europe and the world, with its membership continually expanding.
Stefan K. Nilsson, Lipigon's CEO, also participates in the conference.
"ELC is a significant conference for us to attend, both to showcase our results to the experts advising major pharmaceutical companies in our field and to stay abreast of the latest developments in the research field while assessing competition and new ideas," says Stefan K. Nilsson.
For more information about the research meeting, please visit the ELC website.
For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: [email protected]
Phone: +46 705 78 17 68
The following documents can be retrieved from beQuoted
Lipigon-presents-at-the-ELC-scientific-meeting-in-Tutzing-Ge.pdf About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigons initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA-drug Lipisense® for the treatment of hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.
The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 